Armata Pharmaceuticals, Inc.
ARMP Healthcare Biotechnology
Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 548.9%, free cash flow fell 18.0% and total debt rose 152.4%, each against the same quarter a year earlier.
Follow ARMP
Armata Pharmaceuticals, Inc. (ARMP) Piotroski F-score
Armata Pharmaceuticals, Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | 0.00 |
| FY2024 | 3 | 1.00 |
| FY2023 | 2 | 0.00 |
| FY2022 | 2 | (2.00) |
| FY2017 | 4 | 2.00 |
| FY2016 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (212.83%) | (20.47%) | Fail | 0 |
| Positive operating cash flow | (25.76m) | (37.55m) | Fail | 0 |
| Rising return on assets | (212.83%) | (20.47%) | Fail | 0 |
| Cash flow above net income | 148.04m | (18.63m) | Pass | 1 |
| Falling long-term leverage | 3.15 | 0.60 | Fail | 0 |
| Rising current ratio | 1.19 | 0.23 | Pass | 1 |
| No new shares issued | 36,239,000 | 36,161,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.06 | 0.06 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| SEER Seer, Inc. compare | 5 |
| GNLX Genelux Corporation compare | 3 |
| ARMP Armata Pharmaceuticals, Inc. | 3 |
| FHTX Foghorn Therapeutics Inc. compare | 2 |
| NRXP NRx Pharmaceuticals, Inc. compare | — |
| ENGN enGene Therapeutics Inc compare | — |
| LENZ LENZ Therapeutics, Inc. compare | — |
| NERV Minerva Neurosciences, Inc compare | — |
| HURA TuHURA Biosciences, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover